Mixed Monoclonal Antibody Cocktail for Cancer Immunotherapy from China
A blend of multiple monoclonal antibodies (e.g., pembrolizumab and nivolumab derivatives) designed for immunotherapy treatment of solid tumors. It is a mixed immunological product not in retail sale, so it falls under tariff item 3002.14.00.
Duty Rate — China → Canada
0%
Import Tips
• Ensure the cocktail is in bulk and not in measured doses or retail packs
• Provide documentation of each antibody component and their mixing for customs
• Check if a clinical trial authorization is required from Health Canada